Tag: Peripheral arterial disease

Further evaluation needed: Therapeutic angiogenesis in the treatment of PAD

Lars Norgren talks to Vascular News about therapeutic angiogenesis in the treatment of peripheral arterial disease (PAD). He points out that further evaluation in...

Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD...

The National Institute for Health and Care Excellence (NICE) has published the final appraisal determination (FAD) recommending the use of Xarelto (rivaroxaban) by the...
limflow stent

LimFlow receives FDA approval for US study of minimally-invasive technology designed...

LimFlow has announced that the US Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) for the PROMISE II pivotal study of...

Peripheral arterial disease risk hinges on health factors and demographics, including...

A recent study found that being a smoker, having diabetes, and also having a history of coronary heart disease or stroke increases the lifetime...

Rex Medical receives 510k clearance for Revolution Peripheral Atherectomy System

Rex Medical recently announced that it has received 510k clearance from the US Food and Drug Administration (FDA) for the Revolution Peripheral Atherectomy System. Regulatory...

CIRSE 2019: New Cook Medical paclitaxel data confirm safety of Zilver...

New data on the use of Zilver PTX, Cook Medical’s paclitaxel-coated stent for peripheral arterial disease (PAD), confirm the safety of the device. These...

Statins linked with reduced mortality in PAD patients, even when started...

Statins are linked with reduced mortality in patients with peripheral arterial disease, even when started late after diagnosis, reports a study presented recently at...

Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study

Cardiovascular Systems recently announced that the first patient has been enrolled in the REACH PVI study. The purpose of this study is to prospectively...

Cardiovascular Systems announces first patient enrolled in REACH PVI clinical study

Cardiovascular Systems recently announced that the first patient has been enrolled in the REACH PVI study. The purpose of this study is to prospectively...

Tack Endovascular System launches in the USA, first commercial use announced

Intact Vascular has announced the first commercial use of its Tack Endovascular System in multiple sites across the USA. Recently FDA-approved for above-the-knee interventions,...

Tomographic 3D ultrasound imaging “the way forward” for vascular surgeons

Steven Rogers (Manchester, UK) presented the case for using contrast-enhanced tomographic 3D ultrasound imaging for peripheral arterial disease, telling the audience at Charing Cross...
SFDI

New study points to SFDI as promising technology for assessing patients...

New evidence supports the utility of spatial frequency domain imaging (SFDI) for identifying compromised circulation in patients at risk of peripheral arterial disease (PAD)....

Depression and peripheral arterial disease: A call to action

With “an indisputable association between depression and peripheral arterial disease (PAD)”—nearly a third of PAD patients experience comorbid depression or depressive symptoms—Joel Ramirez and...
cigarette

Smoking cigarettes associated with increased risk of peripheral arterial disease in...

African Americans who smoke cigarettes are more likely than those who do not smoke to develop peripheral arterial disease (PAD), according to new research...
cigarette

Smoking cigarettes associated with increased risk of peripheral arterial disease in...

African Americans who smoke cigarettes are more likely than those who do not smoke to develop peripheral arterial disease (PAD), according to new research...

Tack Endovascular System launches in the EU with first commercial use...

The first commercial use of the Tack Endovascular System (Intact Vascular) has taken place in multiple hospitals within Germany. A novel therapy for dissection...

PCSK9 inhibitors, rivaroxaban and a diabetes drug are major milestones in...

Michael Jaff (Newton, USA) outlines the major recent developments in best medical therapy that will impact the treatment of peripheral arterial disease (PAD) at...

Enrolment complete in T.I.N.T.I.N. study

iVascular has announced the completion of enrolment of patients in its T.I.N.T.I.N. (Treatment with the Luminor DCB and the iVolution self-expanding stent) study. The effectiveness...

First European patients treated with Peripheral Orbital atherectomy system

The first patients in Germany have been treated with the Stealth 360 Peripheral Orbital Atherectomy System (OAS; Cardiovascular Systems Inc). The German cases represent...

First US patient enrolled in ILLUMENATE BTK study of Stellarex 0.014...

The first US patient has been enrolled in the Stellarex ILLUMENATE below-the-knee (BTK) investigational device exemption (IDE) study, led by principal investigators Bill Gray...

Similar patency outcomes in women and men treated with Stellarex DCB

A study presented at VIVA 2018 (5–8 November, Las Vegas, USA) by Maureen Kohi, associate professor of Clinical Radiology, University of California, San Francisco,...

12-Month data from PREVEIL study of SurVeil DCB presented at VIVA

Data from the PREVEIL early feasibility study of the SurVeil drug-coated balloon (DCB, Surmodics) were shared in a late-breaking clinical trial presentation at the...

TOBA II trial meets primary and secondary endpoints at one-year

The Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial has successfully achieved both primary and secondary endpoints. One year results from the TOBA...

New Zilver PTX global data finds 76% freedom from TLR at...

Results from an aggregated data analysis of the use of the Zilver PTX drug-eluting peripheral stent (DES; Cook Medical) in challenging patient populations concluded...

IN.PACT SFA Trial five-year data and Total IN.PACT All-Subjects analysis presented...

  The five-year and final results from the pivotal IN.PACT SFA Trial and one-year all-subjects results from the Total IN.PACT Pooled Analysis of the IN.PACT...

Positive outcomes for Eluvia stent in long lesion IMPERIAL sub-study

Clinical outcomes from the IMPERIAL Long Lesion Sub-study were presented at VIVA (5–8 November, Las Vegas, USA) demonstrating that the Eluvia drug-eluting vascular stent...

Consider intravascular lithotripsy when treating calcified femoropopliteal arteries

 Treating severely calcified arteries by endovascular means is still a challenge, although atherectomy, stents and lithotripsy are all techniques that are employed. Lithotripsy (also...

Five-year evaluation of Zilver PTX stent in a real-world population continues...

Five-year results from a Japanese post-market surveillance study aimed at evaluating the Zilver PTX drug-eluting stent (DES) in a real-world population show consistently positive...
Xarelto

Bayer announces new licensed indication for use of Xarelto in patients...

Xarelto, co-administered with aspirin, is indicated in the EU for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or...

IN.PACT Admiral DCB launched in Japan

Medtronic plc has announced the full commercial launch of the IN.PACT Admiral drug-coated balloon (DCB) in Japan. The launch follows the completion of a...

LIBERTY 360° two-year data show high freedom from major amputation in...

Two-year outcomes from the LIBERTY 360° study have shown a marked improvement across all Rutherford classes, as well as high freedom from major amputation....

Ra Medical files statement for proposed initial public offering

Ra Medical Systems has filed a registration statement on Form S-1 with the US Securities and Exchange Commission relating to a proposed initial public...

Medtronic receives US FDA clearance for 200mm and 250mm IN.PACT Admiral...

Medtronic has announced that it has received US FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral drug-coated balloon (DCB) to treat...

First US implants of MicroStent for peripheral arterial disease take place

MicroStent (Micro Medical Solutions), a vascular stent designed to reduce below-the-knee amputations caused by critical limb ischaemia (CLI) resulting from peripheral arterial disease (PAD)...

Sanford Health enters agreement to develop infusion system

Sanford Health and Freudenberg Medical, a global developer and manufacturer for the medical device industry, have entered into a joint research and development agreement...

US FDA clears CorPath GRX system for use in peripheral vascular...

Corindus has announced receiving 510(k) clearance from the US Food and Drug Administration (FDA) for use of the CorPath GRX system in peripheral vascular...

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical outcomes...

Medtronic launches European below-the-knee clinical study of drug-coated balloon

Medtronic has launched the IN.PACT BTK study to evaluate the effectiveness of using a drug-coated balloon in patients with below-the-knee (BTK) peripheral artery disease. This...

UK All Party Parliamentary Group condemns peripheral arterial disease treatment “postcode...

The All Party Parliamentary Group on Vascular Disease has released its latest report on patient access to technologies for the diagnosis and treatment of...

EUCLID trial to analyse monotherapy of ticagrelor versus clopidogrel in patients...

Despite “overwhelming data” demonstrating the efficacy of antiplatelet therapy in heart disease and stroke, data for antiplatelet therapy for peripheral arterial disease (PAD) are...

Medtronic receives FDA approval for IN.PACT Admiral DCB 150mm lengths

Medtronic has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) in longer, 150mm lengths. The 150mm length...

Aspirin plus ticagrelor may reduce cardiovascular and limb events in peripheral...

Data from the PEGASUS-TIMI 54 trial indicate that the use of aspirin plus ticagrelor (Brilinta, AstraZeneca) in patients with prior myocardial infarction and concomitant...

Mimics trial finds higher patency for Veryan helical stent over straight...

Results from Veryan’s Mimics randomised controlled trial have been published in the latest issue of Circulation: Cardiovascular Interventions. Use of the BioMimics 3D helical...